Loading clinical trials...
Loading clinical trials...
Transthyretin amyloidosis (aTTR) initially described as a rare disease, became the most serious hereditary polyneuropathy of adult onset and family screening has made it possible to identify and follo...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
NCT06563895 · Amyloidosis, Amyloid Cardiomyopathy, and more
NCT06465810 · Transthyretin Amyloidosis, ATTR-CM, and more
NCT07358078 · Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903 · Transthyretin Amyloidosis With Cardiomyopathy
NCT05758493 · Amyloidosis, Transthyretin Amyloidosis
CHU de Nîmes
Nîmes
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions